High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays

Toxicology and Applied Pharmacology

Volumn 288, Issue 2, 2015, Pages 249-257

  Gilchrist, Kristin H ^a   Lewis, Gregory F ^a   Gay, Elaine A ^a   Sellgren, Katelyn L ^a   Grego, Sonia ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

Arrhythmia; Automated analysis; Field potential duration; Human induced pluripotent stem cell derived cardiomyocytes; Microelectrode array; QT prolongation

Indexed keywords

AMIODARONE; CISAPRIDE; FLECAINIDE; OUABAIN; POTASSIUM CHANNEL HERG; RANOLAZINE; TERFENADINE; VERAPAMIL;

ARTICLE; CONCENTRATION RESPONSE; DRUG EXPOSURE; DRUG RESPONSE; ELECTRIC POTENTIAL; HEART ARRHYTHMIA; HEART MUSCLE CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MICROELECTRODE; PLURIPOTENT STEM CELL; PREDICTIVE VALUE; QT PROLONGATION; REPOLARIZATION; SIGNAL PROCESSING; CELL CULTURE; CELL DIFFERENTIATION; CHEMICALLY INDUCED; COMPUTER PROGRAM; DEVICES; DOSE RESPONSE; DRUG EFFECTS; EQUIPMENT DESIGN; HEART RATE; LABORATORY AUTOMATION; MEMBRANE POTENTIAL; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; RISK ASSESSMENT; SIGNAL NOISE RATIO; TIME; TOXICITY TESTING;

ARRHYTHMIAS, CARDIAC; AUTOMATION, LABORATORY; CELL DIFFERENTIATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT DESIGN; HEART RATE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MEMBRANE POTENTIALS; MICROELECTRODES; MYOCYTES, CARDIAC; RISK ASSESSMENT; SIGNAL PROCESSING, COMPUTER-ASSISTED; SIGNAL-TO-NOISE RATIO; SOFTWARE; TIME FACTORS; TOXICITY TESTS;

EID: 84942365564     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.07.024     Document Type: Article

References (22)

1. Cerignoli F., Charlot D., Whittaker R., Ingermanson R., Gehalot P., Savchenko A., Gallacher D.J., Towart R., Price J.H., McDonough P.M., Mercola M. High throughput measurement of Ca(2)(+) dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. J. Pharmacol. Toxicol. Methods 2012, 66:246-256.
2. Chi K.R. Revolution dawning in cardiotoxicity testing. Nat. Rev. Drug Discov. 2013, 12:565-567.
3. Clements M., Thomas N. High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. Toxicol. Sci. 2014, 140:445-461.
4. Guo L., Abrams R.M., Babiarz J.E., Cohen J.D., Kameoka S., Sanders M.J., Chiao E., Kolaja K.L. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 2011, 123:281-289.
5. Guo L., Qian J.Y., Abrams R., Tang H.M., Weiser T., Sanders M.J., Kolaja K.L. The electrophysiological effects of cardiac glycosides in human iPSC-derived cardiomyocytes and in guinea pig isolated hearts. Cell. Physiol. Biochem. 2011, 27:453-462.
6. Guo L., Coyle L., Abrams R.M., Kemper R., Chiao E.T., Kolaja K.L. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol. Sci. 2013, 136:581-594.
7. Harris K., Aylott M., Cui Y., Louttit J.B., McMahon N.C., Sridhar A. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol. Sci. 2013, 134:412-426.
8. Kramer J., Obejero-Paz C.A., Myatt G., Kuryshev Y.A., Bruening-Wright A., Verducci J.S., Brown A.M. MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci. Rep. 2013, 3:2100.
9. Lawrence C.L., Pollard C.E., Hammond T.G., Valentin J.P. In vitro models of proarrhythmia. Br. J. Pharmacol. 2008, 154:1516-1522.
10. Liang P., Lan F., Lee A.S., Gong T., Sanchez-Freire V., Wang Y., Diecke S., Sallam K., Knowles J.W., Wang P.J., Nguyen P.K., Bers D.M., Robbins R.C., Wu J.C. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 2013, 127:1677-1691.
11. Ma J., Guo L., Fiene S.J., Anson B.D., Thomson J.A., Kamp T.J., Kolaja K.L., Swanson B.J., January C.T. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H2006-H2017.
12. Navarrete E.G., Liang P., Lan F., Sanchez-Freire V., Simmons C., Gong T., Sharma A., Burridge P.W., Patlolla B., Lee A.S., Wu H., Beygui R.E., Wu S.M., Robbins R.C., Bers D.M., Wu J.C. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 2013, 128:S3-S13.
13. Noble D. Mechanism of action of therapeutic levels of cardiac glycosides. Cardiovasc. Res. 1980, 14:495-514.
14. Nozaki Y., Honda Y., Tsujimoto S., Watanabe H., Kunimatsu T., Funabashi H. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation. Toxicol. Appl. Pharmacol. 2014, 278:72-77.
15. Pradhapan P., Kuusela J., Viik J., Aalto-Setala K., Hyttinen J. Cardiomyocyte MEA data analysis (CardioMDA)-a novel field potential data analysis software for pluripotent stem cell derived cardiomyocytes. PLoS One 2013, 8:e73637.
16. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., Camm A.J., Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58:32-45.
17. Sager P.T. Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes. Br. J. Pharmacol. 2008, 154:1544-1549.
18. Sager P.T., Gintant G., Turner J.R., Pettit S., Stockbridge N. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am. Heart J. 2014, 167:292-300.
19. Sirenko O., Crittenden C., Callamaras N., Hesley J., Chen Y.W., Funes C., Rusyn I., Anson B., Cromwell E.F. Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells. J. Biomol. Screen. 2013, 18:39-53.
20. Valentin J.P., Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J. Pharmacol. Toxicol. Methods 2008, 58:77-87.
21. Wang L., Wible B.A., Wan X., Ficker E. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J. Pharmacol. Exp. Ther. 2007, 320:525-534.
22. Yamazaki K., Hihara T., Taniguchi T., Kohmura N., Yoshinaga T., Ito M., Sawada K. A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval. Toxicol. In Vitro 2012, 26:335-342.